1. Key Insights 2. Executive summary 3. Methodology 4. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Patient Overview at a Glance 4.1. Total Patient Share (%) Distribution of CIDP in 2017 4.2. Total Patient Share (%) Distribution of CIDP in 2030 5. Chronic inflammatory demyelinating polyneuropathy (CIDP): Disease Background and Overview 5.1. Introduction 5.2. Classification 5.3. Clinical Presentation 5.4. CIDP versus Guillain-Barre Syndrome 5.4.1. Disease course 5.5. Disease associations with CIDP 5.6. Pathogenesis of CIDP 5.6.1. FcRN role in the CIDP 5.7. Diagnosis 5.7.1. Diagnostic criteria 5.7.2. Differential diagnosis 5.7.3. AAN electrodiagnostic criteria 5.7.4. Koski et al’s criteria 5.7.5. European Federation of Neurological Societies and the Peripheral Nerve Society 6. Organizations 7. Epidemiology and Patient Population 7.1. Key Findings 8. Total Prevalent Population of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 7MM 9. United States Epidemiology 9.1. Assumptions and Rationale 9.2. Total Prevalent Population of CIDP in the United States 9.3. Gender-Specific Prevalent Population of CIDP in the United States 9.4. Clinical Subtype based Diagnosed cases of CIDP in the United States 9.5. Age-Specific Prevalent Population of CIDP in the United States 10. EU5 Epidemiology 10.1. Germany Epidemiology 10.1.1. Assumptions and Rationale 10.1.2. Total Prevalent Population of CIDP in Germany 10.1.3. Gender-Specific Prevalent Population of CIDP in Germany 10.1.4. Clinical Subtype based on Diagnosed cases of CIDP in Germany 10.1.5. Age-Specific Prevalent Population of CIDP in Germany 10.2. France Epidemiology 10.2.1. Assumptions and rationale 10.2.2. Total Prevalent Population of CIDP in France 10.2.3. Gender-Specific Prevalent Population of CIDP in France 10.2.4. Clinical Subtype based on Diagnosed cases of CIDP in France 10.2.5. Age-Specific Prevalent Population of CIDP in France 10.3. Italy Epidemiology 10.3.1. Assumptions and Rationale 10.3.2. Total Prevalent Population of CIDP in Italy 10.3.3. Gender-Specific Prevalent Population of CIDP in Italy 10.3.4. Clinical Subtype based on Diagnosed cases of CIDP in Italy 10.3.5. Age-Specific Prevalent Population of CIDP in Italy 10.4. Spain Epidemiology 10.4.1. Assumptions and Rationale 10.4.2. Total Prevalent Population of CIDP in Spain 10.4.3. Gender-Specific Prevalent Population of CIDP in Spain 10.4.4. Clinical Subtype based on Diagnosed cases of CIDP in Spain 10.4.5. Age-Specific Prevalent Population of CIDP in Spain 10.5. United Kingdom Epidemiology 10.5.1. Assumptions and Rationale 10.5.2. Total Prevalent Population of CIDP in the UK 10.5.3. Gender-Specific Prevalent Population of CIDP in the UK 10.5.4. Clinical Subtype based Diagnosed cases of CIDP in the UK 10.5.5. Age-Specific Prevalent Population of CIDP in the UK 10.6. Japan Epidemiology 10.6.1. Assumptions and Rationale 10.6.2. Total Prevalent Population of CIDP in Japan 10.6.3. Gender-Specific Prevalent Population of CIDP in Japan 10.6.4. Clinical Subtype based on Diagnosed cases of CIDP in Japan 10.6.5. Age-Specific Prevalent Population of CIDP in Japan 11. KOL Views 12. Appendix 12.1. Report Methodology 13. DelveInsight Capabilities 14. Disclaimer 15. About DelveInsight

Table 1: Major phenotypic variants of CIDP Table 2: Clinical subtypes of chronic inflammatory demyelinating polyneuropathy Table 3: Comparison of CIDP and subtypes Table 4: Contrast of CIDP and Guillain Barre Syndrome Table 5: Differential Diagnosis Table 6: American Academy of Neurology Ad Hoc Subcommittee - electrodiagnostic criteria Table 7: Koski et al’s criteria for chronic inflammatory demyelinating polyneuropathy (CIDP) Table 8: Investigations to be considered Table 9: EFNS/PNS Diagnostic Criteria for CIDP Table 10: Total Prevalent Population of CIDP in the 7MM (2017-2030) Table 11: Total Prevalent Population of CIDP in the US (2017-2030) Table 12: Gender-Specific Prevalence of CIDP in the US (2017-2030) Table 13: Clinical Subtype based Diagnosed cases of CIDP in the US (2017-2030) Table 14: Age-Specific Prevalence of CIDP in the US (2017-2030) Table 15: Total Prevalent Population of CIDP in Germany (2017-2030) Table 16: Gender-Specific Prevalence of CIDP in Germany (2017-2030) Table 17: Clinical Subtype based Diagnosed cases of CIDP in Germany (2017-2030) Table 18: Age-Specific Prevalence of CIDP in Germany (2017-2030) Table 19: Total Prevalent Population of CIDP in France (2017-2030) Table 20: Gender-Specific Prevalence of CIDP in France (2017-2030) Table 21: Clinical Subtype based Diagnosed cases of CIDP in France (2017-2030) Table 22: Age-Specific Prevalence of CIDP in France(2017-2030) Table 23: Total Prevalent Population of CIDP in Italy (2017-2030) Table 24: Gender-Specific Prevalence of CIDP in Italy (2017-2030) Table 25: Clinical Subtype based Diagnosed cases of CIDP in Italy (2017-2030) Table 26: Age-Specific Prevalence of CIDP in Italy (2017-2030) Table 27: Total Prevalent Population of CIDP in Spain (2017-2030) Table 28: Gender-Specific Prevalence of CIDP in Spain (2017-2030) Table 29: Clinical Subtype based Diagnosed cases of CIDP in Spain (2017-2030) Table 30: Age-Specific Prevalence of CIDP in Spain (2017-2030) Table 31: Total Prevalent Population of CIDP in the UK (2017-2030) Table 32: Gender-Specific Prevalence of CIDP in the UK (2017-2030) Table 33: Clinical Subtype based Diagnosed cases of CIDP in the UK (2017-2030) Table 34: Age-Specific Prevalence of CIDP in the UK (2017-2030) Table 35: Total Prevalent Population of CIDP in Japan (2017-2030) Table 36: Gender-Specific Prevalence of CIDP in Japan (2017-2030) Table 37: Clinical Subtype based Diagnosed cases of CIDP in Japan (2017-2030) Table 38: Age-Specific Prevalence of CIDP in Japan (2017-2030) Figure 1: Schematic presentation of the distribution of demyelinating lesions Figure 2: Immunopathogenesis of Chronic Inflammatory Demyelinating Neuropathy Figure 3: Immunopathogenesis of Chronic Inflammatory Demyelinating Neuropathy Figure 4: Algorithm of Diagnostic procedures Figure 5: Total Prevalent Population of CIDP in the 7MM (2017-2030) Figure 6: Total Prevalent Population of CIDP in the US (2017-2030) Figure 7: Gender-Specific Prevalence of CIDP in the US (2017-2030) Figure 8: Clinical Subtype based Diagnosed cases of CIDP in the United States (2017-2030) Figure 9: Age-Specific Prevalence of CIDP in the US (2017-2030) Figure 10: Total Prevalent Population of CIDP in Germany (2017-2030) Figure 11: Gender-Specific Prevalence of CIDP in Germany (2017-2030) Figure 12: Clinical Subtype based Diagnosed cases of CIDP in Germany (2017-2030) Figure 13: Age-Specific Prevalence of CIDP in Germany (2017-2030) Figure 14: Total Prevalent Population of CIDP in France (2017-2030) Figure 15: Gender-Specific Prevalence of CIDP in France (2017-2030) Figure 16: Clinical Subtype based Diagnosed cases of CIDP in France (2017-2030) Figure 17: Age-Specific Prevalence of CIDP in France (2017-2030) Figure 18: Total Prevalent Population of CIDP in Italy (2017-2030) Figure 19: Gender-Specific Prevalence of CIDP in Italy (2017-2030) Figure 20: Clinical Subtype based Diagnosed cases of CIDP in Italy (2017-2030) Figure 21: Age-Specific Prevalence of CIDP in Italy (2017-2030) Figure 22: Total Prevalent Population of CIDP in Spain (2017-2030) Figure 23: Gender-Specific Prevalence of CIDP in Spain (2017-2030) Figure 24: Clinical Subtype based Diagnosed cases of CIDP in Spain (2017-2030) Figure 25: Age-Specific Prevalence of CIDP in Spain (2017-2030) Figure 26: Total Prevalent Population of CIDP in the UK (2017-2030) Figure 27: Gender-Specific Prevalence of CIDP in the UK (2017-2030) Figure 28: Clinical Subtype based Diagnosed cases of CIDP in the UK (2017-2030) Figure 29: Age-Specific Prevalence of CIDP in the UK (2017-2030) Figure 30: Total Prevalent Population of CIDP in Japan (2017-2030) Figure 31: Gender-Specific Prevalence of CIDP in Japan (2017-2030) Figure 32: Clinical Subtype based Diagnosed cases of CIDP in Japan (2017-2030) Figure 33: Age-Specific Prevalence of CIDP in Japan (2017-2030)